EMA Withdrawn: Tremelimumab AstraZeneca (tremelimumab) — AstraZeneca AB

View source ↗

Summary

EMA has withdrawn the marketing authorization for tremelimumab for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tremelimumab (tremelimumab)

Snippet

Status: Withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: AstraZeneca AB. Decision date: 04/09/2023